Anti-CD1a [CBT6] Fc Silent Antibody, Human IgG1 kappa - Creative Biolabs
Book a Meeting

Anti-CD1a [CBT6] Fc Silent Antibody, Human IgG1 kappa (CAT#: BioBet-F498P) Datasheet

Product Type
Fc Silent Antibody
Description
The Fc-mediated effector functions of antibodies include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), and have been shown to be crucial for the therapeutic efficacy of most clinically approved antibodies. However, engaging immune effectors through FcγR and complement interactions may be detrimental to certain mAb mechanisms of action and so Fc-null or -silenced antibodies may be desired.

Creative Biolabs uses site-directed mutagenesis technology to generate Fc-silenced antibody with reduced effector functions. The mutated Fc domains eliminate the binding of Fc receptors (FcγR, FcR), thereby leading to a significant reduction in ADCC and CDC in comparison to WT IgG.
Immunogen
This antibody was raised by immunizing mice with the human CD1a protein.
Species
Human
Cross reactivity
Human
Host
Human
Clonality
Monoclonal
Isotype
IgG1 kappa
Clone Number
CBT6
Conjugation
Unconjugated
Source
This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Buffer
PBS only
Application
FC, IP, IHC, EL, IP
Storage Instructions
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For lon...
Target
CD20
Alternative Names
MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany